SI-722

SI-722 is a novel chemical compound developed by Seikagaku that consists of a steroid conjugated with chondroitin sulfate using proprietary glycosaminoglycan (GAG) modification technology and drug delivery systems. The drug is designed for intravesical (bladder) administration, where it provides sustained release of the steroid to exert anti-inflammatory effects. Its primary indication is for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS), aiming to improve symptoms such as frequent urination and bladder pain. The precise mechanism of action has not been fully defined, but it leverages the anti-inflammatory properties of steroids delivered via a GAG-based carrier[1][2][4][8]. The specific steroid used in SI-722 has not been disclosed in public sources. The product failed to meet its primary endpoint in a Phase III clinical study as of May 2022, and future development plans are under consideration by Seikagaku[8]. Mechanism details remain undefined.